The amended Rotterdam consensus has PCOS with evidence-based criteria of at least two of the following needs: (a) clinical or biochemical hyperandrogenism, (b) ovulatory dysfunction, and (c) polycystic ovary morphology (PCOM) or high anti-Mullerian hormone (AMH) [2]. Here, AMH is linked to polycystic ovary syndrome.